Edged US has secured $2 billion in cumulative financing this year. This funding accelerates the expansion of its sustainable and AI-ready digital infrastructure across key United States markets. The milestone includes the successful pricing of a $1.3 billion Senior Secured Notes offering completed in April 2026. 

The bond supports the simultaneous development of multiple data centre sites serving different customers under long-term lease agreements. The financing backs two major build-to-suit facilities within the company’s Atlanta and Chicago campuses. Morgan Stanley acted as Lead Left Bookrunner for the notes offering. 

The execution reflects growing demand for high-performance, energy-efficient, and scalable digital infrastructure tailored to AI training and inference workloads. The construction loan supporting the 200 MW Council Bluffs campus complements the effort by securing continued development capacity. The company plans to expand across major U.S. hubs. 

The strategy positions Edged US to meet rising enterprise and hyperscale AI requirements. The scale and pace of these developments show how the firm aims to meet future demand with sustainable systems. The financing momentum allows the company to move with speed and precision as market conditions evolve around AI growth and cloud acceleration.

Financing Momentum Supports AI-Ready Data Centre Design

The year-to-date financing includes a construction loan for the Council Bluffs campus arranged by TD Securities and Crédit Agricole CIB. The company views these transactions as signals of market confidence. The demand for high-performance digital infrastructure continues to rise. 

This trend drives strong investor interest in scalable platforms with clear sustainability strategies and fast deployment capabilities. Edged US designs its data centres to meet the next generation of compute environments. 

The firm’s technology includes liquid-to-chip cooling and modular deployment options. These features support AI workloads without raising operational complexity for clients. The design also reduces resource consumption. This combination strengthens reliability and efficiency across the company’s portfolio.

The company’s build-to-suit approach gives customers predictable performance. It also gives them dedicated space for high-density racks and AI training clusters. This model helps large enterprises plan for long-term capacity. It also supports the broader shift from conventional data centre architecture to specialised AI infrastructure.

Sustainable Cooling and Efficiency Drive Market Differentiation

Edged US advances sustainable, high-performance data infrastructure for AI workloads. Source: Created by Ventureburn

Edged US highlights sustainability as a core part of its value proposition. The firm’s ThermalWorks waterless cooling system eliminates water usage in daily operations. This approach helps customers scale AI workloads without high environmental costs.  The technology also supports regions facing water scarcity. 

The focus on efficiency aligns with broader industry trends across cloud and AI operations. The company targets a design PUE of 1.15 across its portfolio. This efficiency target helps customers reduce energy waste. It also gives them predictability when modelling long-term costs. 

The platform offers scalable deployment options that allow customers to add capacity in phases. This helps organisations grow at a realistic pace while maintaining operational stability. Edged US operates or develops campuses in strategic markets including Atlanta, Chicago, Columbus, Council Bluffs, Dallas, Des Moines, Kansas City and Phoenix. 

Each market supports different customer needs. Some sites are built for hyperscalers. Others support technology firms or enterprise clients transitioning to AI-driven workflows. The combination of geographic spread and specialised design strengthens the company’s competitive position.

The company’s ability to pair sustainability with performance attracts strong investor support. This dynamic creates confidence in the long-term stability of its platform. It also aligns with industry expectations for responsible digital infrastructure development.

More News: Countable Labs Raises $26 Million to Advance Single-Molecule PCR Technology

Expanding Platform to Meet AI and Cloud Growth

Edged US continues to scale its infrastructure as cloud and AI workloads grow. The financing milestone reflects a market environment where speed, efficiency and sustainability influence decisions. Customers now require partners who can deliver capacity quickly. They also need assurance that the infrastructure supporting their AI models is resilient and resource-efficient.

According to the company, high-performance digital infrastructure sits at the centre of modern technology growth. AI workloads require dense power, strong cooling systems and stable environments. These needs shape the design of new campuses. They also influence long-term planning. Edged US aims to build facilities that match these requirements accurately.

The company’s leadership believes the financing will help it execute its development pipeline with confidence. It also ensures it can maintain a consistent pace of construction across several metro areas. The scale of the raise gives Edged US flexibility to refine its technologies and deliver improved services.

Customers increasingly expect partners to move rapidly. They expect strong performance without compromising environmental goals. Edged US continues to position itself as a reliable partner for long-term growth.

To support broader strategic goals, investors expect the firm to continue expanding its platform. This includes refining AI-ready design elements and enhancing liquid-to-chip cooling capabilities. It may also include additional financing to accelerate deployment.

The company’s mission focuses on building infrastructure for the digital economy. It aims to support AI growth by offering infrastructure that keeps pace with demand. This aligns with its expansion efforts across the United States.

To further inform readers on sustainable data centre strategies, the U.S. Department of Energy provides insight into energy-efficient infrastructure design (external source). Readers can explore broader trends shaping the sector. This helps them understand how environmental standards influence new infrastructure models.

To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.

The post Edged US Secures $2 Billion to Expand AI-Ready Data Infrastructure appeared first on Ventureburn.

Countable Labs raises $26 million to accelerate the development and commercial rollout of its single-molecule PCR technology. The round was led by ARCH Venture Partners, with participation from F-Prime Capital and Primer Ventures. The raise strengthens its capacity to deliver genomic measurement tools.

The business developed Countable PCR, a platform that offers higher sensitivity and clarity than digital PCR. The method removes the need for Poisson correction. It also avoids standard curves. The approach aims to give laboratories more confidence when measuring rare biological signals. 

The company said this clarity helps teams working in genomics make better decisions faster. Fit-for-purpose solutions that address cell and gene therapy, minimal residual disease testing, biomarker validation, and vaccine quality control are supported by the new capital. 

These markets are in greater need of accuracy, and in this regard, the company views Countable PCR as a practical solution for labs looking for accuracy that accommodates a wider dynamic range and simpler workflows. 

Countable Labs hired a new VP of Global Sales for their commercial rollout. The addition of the VP shows that the company is dedicated to increasing their reach in several major markets. The new hire has substantial experience in sales of tools for life sciences.

Countable PCR Targets Critical Genomic Applications

Countable PCR is designed for sensitive applications where small biological signals matter. Its single-molecule approach captures information that traditional PCR and digital PCR miss. The company said this level of detail is essential for understanding genetic markers, detecting rare events, and validating biomarkers linked to disease.

The technology includes a 10-colour capability. This enables a wide range of multiplexing options that support complex genomic studies. The platform is purpose-built for research and industrial settings. It aims to help laboratories detect fusions, track markers of genome integrity, and measure inherited patterns across complex samples. 

The company said these abilities help teams uncover insights that would remain hidden using standard tools. The method uses molecular linkage to understand genetic patterns. This capability allows scientists to see how different regions of the genome relate to each other. 

That information strengthens research across oncology, diagnostics, and therapy development. The platform aims to open new possibilities in genomic science, providing the clarity needed for high-stakes decisions. Countable Labs believes 2026 will be a decisive year for the technology. 

Early studies showed strong performance in clinical samples. These results validated the robustness of the platform. The company now prepares to scale production and introduce category-specific products for laboratories that demand precision and ease of use.

Funding Supports Global Expansion and Product Strategy

Countable Labs scales precision genomic tools for worldwide adoption. Source: Created by Ventureburn

The company plans to use its new funding to expand commercial operations worldwide. It aims to ensure that laboratories seeking precision genomic tools can access Countable PCR without friction. The leadership team said that many segments still rely on digital PCR or next-generation sequencing. 

These methods offer value but can introduce ambiguity. Countable Labs aims to remove this ambiguity by providing a simple and sensitive alternative. The investment from ARCH Venture Partners reflects strong confidence in the platform’s technical foundation. The firm said PCR requires new solutions that offer speed, accuracy, and lower cost. 

It added that Countable Labs reimagined PCR in a way that could support high-volume testing across many sectors. This includes translational science, industrial testing, and advanced research. F-Prime Capital highlighted the potential for broad adoption. 

The firm said that making rare event detection widely accessible will support global health, oncology, and therapy manufacturing. It added that Countable PCR can replace existing methods in areas where cost, complexity, or ambiguity limit progress.

More News: Secretome Therapeutics Raises $30M Series A for Cardiac Cell Therapy Expansion

Positioning for Leadership in Genomic Measurement

Countable Labs positions itself as a company redefining how biology is measured. It offers tools that deliver ten times the sensitivity of standard PCR. It also provides quantitative accuracy beyond what digital PCR and next-generation sequencing currently achieve. 

The company believes these advantages will help laboratories detect rare genomic targets with new confidence. The business plans to grow its presence across oncology, cell and gene therapy, molecular diagnostics, and industrial testing. 

Each segment requires high analytical performance. According to the company, its platform can fulfil these desires with an ease of access that comes naturally with straightforward technology. The company founders said that a simple, sensitive and yet affordable platform capable of enabling large-scale testing will be central to the future of genomic screening. 

Countable PCR offers a perfect fit as a sensitive, yet straightforward, platform. There is clear demand in the market, including in the labs market, for a method that enables detection but does not depend on the use of cumbersome or expensive platforms. 

This funding will also facilitate increased development within the team to create and launch a raft of specialised products targeting use-specific applications that will cement Countable PCR’s position as a go-to choice for ultra-sensitive measurement.

To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.

The post Countable Labs Raises $26 Million to Advance Single-Molecule PCR Technology appeared first on Ventureburn.

Secretome Therapeutics just landed $30 million in Series A funding, thanks mostly to RA Capital Management—those folks really know their way around healthcare investments. This big cash injection is set to push their clinical work forward, ramp up operations, and build out their infrastructure. 

And honestly, it gives their team even more confidence in what they’re building: a regenerative cardiac therapy platform that’s aiming for some pretty big impact. They work by therapies from neonatal cardiac progenitor cells that promote damaged heart tissue to regenerate. 

Secretome are focusing on inflammation and fibrosis, both factors in the development of heart disease. So this funding is like a “point of no return” where things are moving at a much quicker pace. The capital invested isn’t only to advance the research & development; it’s also being put directly into increasing manufacturing capacity for upcoming clinical trials. 

This will position them well to move forward into later development stages and the growing of the internal teams dedicated to regulatory and clinical aspects. In all this the company keeps its eye on a broader goal of bringing advancement to cardiac science not just nationally but globally.

STM-01 Advances Toward Late-Stage Cardiomyopathy Trials

STM-01, which represents the company’s most advanced program, is an innovative cellular therapy targeting the restoration and regeneration of cardiac function. This therapy is designed for Duchenne muscular dystrophy associated cardiomyopathy which, although progressive and harsh, is only one manifestation of the disease process involving the heart. 

It seeks to overcome both the inflammatory response and the fibroblastic remodeling of heart muscle. STM-01 represents a therapy that can affect change in the disease process, and Secretome plans to begin its phase 2 and phase 3 clinical trials in the near future. 

These large clinical trials will eventually lead to approval of the therapy and it is to aid Secretome in speeding its plan for the clinical trials that the new funding is allotted. More specifically, Secretome will allocate the funding towards study site identification, patient selection, recruitment, and logistical planning for the studies. 

In addition, the company is investigating application of the platform technology to address other forms of cardiac dysfunction such as dilated cardiomyopathy and heart failure with preserved ejection fraction, which, like Duchenne MD associated cardiomyopathy, have no effective treatments for the diseased population globally.

RA Capital Investment and Board Leadership Changes

Board changes and investor oversight highlight confidence in cellular therapy innovation. Source: Created by Ventureburn

The Series A round was led exclusively by RA Capital Management. The firm is known for evidence-based investing in life sciences companies. It supports healthcare innovation across early and late development stages. Its participation signals strong confidence in Secretome’s scientific platform.

A partner from RA Capital will join as Board Observer. This role provides governance support and strategic oversight. The investor views STM-01 as a potentially best-in-class therapy. It also highlights strong belief in cellular therapy platforms.

Secretome announced several changes to its Board of Directors. A new director with extensive biotech leadership experience has joined. He brings decades of operational and financial expertise to the company. His background includes multiple successful biotechnology company exits.

A long-serving board member has stepped down from his role. The company expressed gratitude for his contributions during early development stages. His guidance supported clinical and organisational growth. The transition reflects a shift toward late-stage execution priorities.

More News: Cognition Raises $1 Billion to Scale Autonomous Software Engineering

Platform Expansion and Clinical Development 

Secretome Therapeutics is a clinical-stage biotechnology company based in Texas. It focuses on regenerative therapies derived from cardiac progenitor cells. The platform is designed to restore heart function through biological regeneration. It targets inflammation and fibrosis pathways in cardiac disease.

The pipeline includes STM-01 as the lead clinical candidate. It also includes STM-21 in preclinical development stages. These programmes expand the company’s therapeutic reach significantly. They support a broader regenerative medicine strategy.

The Series A funding supports manufacturing expansion and regulatory preparation. It will also accelerate readiness for late-stage clinical trials. The company is now advancing toward pivotal development milestones. This stage is critical for long-term validation and approval potential.

Secretome aims to deliver disease-modifying therapies for cardiac patients. Its approach focuses on repairing underlying biological damage. These pathways are central to heart failure progression and severity. The company is positioned in a high-need therapeutic category.

The next phase will focus on clinical validation and therapeutic scaling. Successful outcomes could position STM-01 as a breakthrough therapy. The company continues building toward long-term pipeline expansion. Its strategy remains centred on regenerative cardiac innovation.

To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.

The post Secretome Therapeutics Raises $30M Series A for Cardiac Cell Therapy Expansion appeared first on Ventureburn.

Cognition has raised $1 billion in Series D financing at a $26 billion valuation. The company builds autonomous AI agents for software engineering. Its flagship agent, Devin, can independently write, test, and deploy code. 

The round was led by Lux Capital, General Catalyst, and 8VC. Other backers included Founders Fund, Alpha Wave, and Ribbit Capital among others. The raise reflects strong investor confidence in AI engineered products. Cognition was founded in 2023 in San Francisco by Scott Wu, Steven Hao, and Walden Yan. 

It has quickly become a leader in AI software agent technology. The company previously raised $400 million at a $10.2 billion valuation in 2025. This year’s round more than doubles that valuation. Cognition has now raised more than $2.5 billion in total funding. Investors say Cognition’s autonomous engineering model distinguishes the company. 

It goes beyond tools that suggest code snippets. Instead, its agents independently complete full software development workflows. This includes planning, coding, debugging, and deployment. The company says this capacity reshapes how software teams operate. Cognition’s growth comes amid rising demand for efficient engineering systems. 

Many firms struggle to find and retain engineering talent. AI agents like Devin promise to augment or automate these roles. This trend may redefine the future of software creation. The raise positions Cognition to scale operations further.

Devin Automates the Full Engineering Cycle

Cognition’s flagship product is Devin, an autonomous software engineer. Unlike traditional coding assistants, Devin executes tasks end to end. It operates without step by step human direction. It interprets task descriptions. It then writes, tests, debugs, and deploys software. Devin combines multiple models into its decision process. 

It uses proprietary systems alongside tools from other providers. This approach allows flexibility and strength in execution. Cognition routes tasks to the most appropriate models for the job. The company reports Devin is used in production by major enterprises. Clients include Goldman Sachs, Mercedes-Benz, Dell, and Santander. 

The US Army and Navy also use Devin for engineering work. Latin America’s largest bank, Itaú, says Devin resolves 70 per cent of vulnerabilities automatically. Systems integrators like Infosys and Cognizant embed the platform in workflows. Cognition’s leadership says Devin’s reach is expanding fast. 

The company said its revenue run rate grew from $37 million to $492 million in one year. It aims to cross $1 billion in annualised revenue soon. The rapid growth mirrors market demand for autonomous engineering tools. The autonomous model is a leap from traditional tools. Many platforms now assist with coding. 

These include Cursor and GitHub Copilot. Both still rely on human direction. Devin instead takes ownership of tasks and executes them completely. This distinction is central to Cognition’s vision. Its leaders believe the next phase of software engineering lies in agents with full autonomy. They argue this reflects a new era in code generation and validation.

Competitive Dynamics in AI Code Markets

Competition in AI coding accelerates the shift toward autonomous agents that execute full software workflows. Source: Created by Ventureburn

The AI coding market is crowded and competitive. Cursor closed a $2.3 billion round in 2025 at a $29.3 billion valuation. It is now in talks to raise up to $2 billion more at around a $50 billion value. GitHub Copilot remains a dominant force backed by Microsoft. OpenAI and Anthropic both heavily invest in coding capabilities.

Cognition argues its agent layer is where durable value will form. It believes models alone will commoditise over time. Instead, value resides in planning, reasoning, and execution layers. These allow autonomous behaviour rather than simple assistance. This distinction shapes Cognition’s strategy and product roadmap.

Cognition also grows through acquisition. In 2025 it acquired Windsurf. This AI code editor brought new users and enterprise revenue. Its SWE-1.6 model became widely used inside the Cognition platform. Finding talent and technology that can scale has been key for the company.

Investors in deep tech like Lux Capital have backed complex long term projects before. The firm and others in this round have supported companies with extended development cycles. Their backing signals belief in Cognition’s architecture and team.

Cognition’s leadership also acknowledges open questions in the market. One key issue is whether enterprises will deploy autonomous agents at scale. Legal, security, and compliance functions must adapt. Many organisations remain cautious about unsupervised AI action on live systems.

More News: ClearNote Health Secures $52 Million to Scale Early Cancer Detection

Scaling Growth Amid Rapid Industry Transformation

Cognition said it will use the new capital to refine its models further. It will also improve the customer experience. The company plans additional product enhancements and partnerships. It aims to expand its global footprint and deepen enterprise adoption. CEO Scott Wu said more than 90 per cent of Cognition’s internal code is now written by Devin. 

If accurate, this makes Cognition one of the most aggressive adopters of its own product. The company said this internal adoption builds confidence in the platform’s capabilities. Wu said the future of software will involve tools that can think and act autonomously. He said Cognition intends to build that future. 

The company sees software engineering as a workflow that can be automated safely. The raise also allows Cognition to remain independent. This was emphasised in the wake of major acquisition activity in the AI sector. High value startups are being bought or merged into larger technology firms. Cognition said it prefers autonomy to control its destiny and drive innovation.

Cognition’s focus on the agent layer rather than the model layer reflects strategic thinking. It argues model performance will improve across the industry. Yet the layer that controls orchestration has lasting competitive potential. Some firms build agents for narrow tasks. Cognition’s approach is broader. 

It treats software engineering as a set of repeatable workflows. Its systems learn and improve from repeated execution. This creates a compounding effect over time. While competition remains strong, Cognition says its growth pace positions it well. It believes its combination of models and execution logic will outpace rivals. 

The company said it plans potential acquisitions to strengthen gaps. Cognition’s record raise highlights expanding investor interest in autonomous AI systems. These tools are now redefining software engineering. They may soon shift how large technology functions operate globally.

To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.

The post Cognition Raises $1 Billion to Scale Autonomous Software Engineering appeared first on Ventureburn.

ClearNote Health has secured $52 million in Series D funding. The company focuses on early detection of deadly cancers. It develops noninvasive blood based diagnostic tools. The funding round brings total capital raised above $185 million. The company aims to scale access to early screening technologies globally.

The round was led by founding investor Mattias Westman. A global long only active manager also co led the investment. Additional participants included Sandy Weill. He is former CEO and chairman of Citigroup. Dr Stephen Quake also participated. He is ClearNote Health co founder from Stanford University.

The company also attracted a Seattle based family office. Several other institutional investors joined the round. These include US and international backers. Investors highlighted strong scientific progress. They also cited growing demand for early cancer detection tools.

ClearNote Health said proceeds will support expansion plans. It will invest in commercial growth. It will also fund clinical study execution. Product development will also receive increased investment. The company aims to scale its Avantect portfolio and Virtuoso platform.

AI and Epigenomics Drive Noninvasive Cancer Innovation

ClearNote Health builds its platform on epigenomic science. It uses blood based signals to detect cancer. These signals reflect biological changes in cells. The system analyses differences between healthy and cancerous samples. It applies machine learning to improve accuracy.

The company’s core technology is the Virtuoso platform. It combines epigenomics with artificial intelligence. It also integrates bioinformatics systems. This allows high sensitivity detection of cancer markers. The platform is designed for early stage identification.

ClearNote Health also develops Avantect tests. These are noninvasive blood tests. They target pancreatic and ovarian cancers. These cancers are often detected late. Early detection can improve treatment outcomes. The company aims to change that timeline.

The Avantect pancreatic test has shown strong performance. It uses a multiomic approach. It combines multiple biological signals. It also uses machine learning optimisation. This improves detection sensitivity and specificity. Clinicians can make faster decisions using these results.

The company said its technology supports clinical precision. It reduces reliance on invasive procedures. It also improves accessibility of screening. ClearNote Health believes early detection is the most important factor. It aims to shift diagnosis earlier in the disease cycle.

Leadership Expansion Signals Commercial Acceleration

Experienced leadership drives scaling of AI-powered cancer diagnostics, accelerating global access to early detection technologies. Source: Created by Ventureburn

ClearNote Health also announced a leadership expansion. Kevin Keegan has been appointed president and chief operating officer. He brings nearly 30 years of diagnostics experience. His background includes roles in oncology and molecular diagnostics.

Keegan previously worked at BD. He also held senior positions at Illumina and Hologic. At Illumina, he led oncology operations. He oversaw launch of a major tumour profiling test. His experience spans global diagnostics commercialisation.

He said ClearNote Health has strong potential. He highlighted its purpose built platform. He believes early diagnosis can transform outcomes. He said he is focused on expanding access to genomic tools. He aims to support patients at elevated risk.

CEO Dave Mullarkey said the appointment strengthens execution. He said the company is entering a scaling phase. He highlighted commercial momentum across products. He also noted increasing market demand. He said leadership depth is essential for expansion.

Investors also welcomed the leadership move. They said experienced operational leadership is critical. They believe ClearNote Health is entering a growth stage. They highlighted strong alignment between science and execution.

More News: Pace Raises $46 Million to Scale AI Insurance Operations

Clinical Expansion and Global Access Strategy

ClearNote Health will expand clinical research programmes. It will scale ongoing studies across cancer types. It will also expand product validation efforts. These studies support regulatory and commercial adoption. The company aims to strengthen clinical confidence.

The firm plans broader global access to its tests. It targets high risk patient populations. It aims to support earlier intervention strategies. It believes noninvasive testing can improve screening rates. It also expects increased adoption in healthcare systems.

The company operates a CLIA certified laboratory. It is also CAP accredited. It holds approval from the New York State Department of Health. Its headquarters are in San Diego. These certifications support clinical reliability.

ClearNote Health has developed its platform at Stanford University origins. It was built in the Stephen Quake laboratory. The system integrates advanced computational biology. It also uses artificial intelligence models. These tools support scalable cancer detection.

The company said demand for early detection is rising. Healthcare systems are under pressure. Costs and late diagnosis remain key challenges. ClearNote Health believes its platform addresses both issues. It aims to provide scalable and affordable diagnostics.

ClearNote Health’s funding reflects rising investment in advanced diagnostic platforms. Early detection technologies continue to attract strong institutional backing.

ClearNote Health’s $52 million Series D strengthens its position in early cancer detection. The company combines epigenomics, machine learning, and clinical diagnostics into a single platform. It now moves into a global scaling phase supported by strong investor and leadership expansion.

To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.

The post ClearNote Health Secures $52 Million to Scale Early Cancer Detection appeared first on Ventureburn.

Pace has raised $46 million in Series B funding. The round was co-led by Thrive Capital and Sequoia Capital. Emergence Capital and Pruven Capital also participated. The company builds AI systems for insurance operations. It focuses on automating complex back office workflows. The new capital will support global scaling.

Pace works with major insurers and brokers. These include The Mutual Group, Newfront, Prudential, and WTW. The company said it has already completed more than 250,000 workflows. These tasks were executed by AI agents. They include policy servicing, claims processing, and data entry operations.

Insurance operations remain highly manual. Many processes depend on documentation and human review. This slows down execution and increases cost. Pace said its AI system reduces these inefficiencies. It integrates directly into internal insurer systems. It also operates across documents, calls, and structured data.

The company said its mission is to close the global protection gap. It estimates this gap at $9 trillion. It believes AI-native operations can improve access to insurance. It also believes automation can reduce friction in claims and underwriting systems.

AI Agents Reshape Core Insurance Workflows

Pace uses AI agents to execute insurance tasks. These agents can navigate internal applications. They can read documents and extract structured data. They can also make phone calls when needed. This allows them to complete end-to-end workflows.

The system supports core insurance functions. These include submission intake, policy servicing, claims handling, and renewals. Pace said these processes are often slow. It believes automation improves speed and accuracy. It also reduces dependency on manual operations teams.

Pace said its platform already delivers measurable impact. At Prudential, it automates thousands of hours of manual work. It supports policy issuance and customer acquisition workflows. At Ryze Claim Solutions, it reduces claim cycle times by 30 percent. At Convex US, it speeds up data ingestion for renewals.

The company said insurers face increasing operational pressure. Customer expectations for speed are rising. Costs remain high across legacy systems. AI-driven automation is becoming a competitive requirement. Pace positions its platform as a solution to this shift.

The company said its agents improve over time. Each completed workflow strengthens system performance. This creates a compounding intelligence loop. It improves both accuracy and execution speed. It also increases system reliability at scale.

Pace said traditional software is not enough. It argues that passive systems cannot solve operational complexity. Its platform is designed to actively execute tasks. This differentiates it from standard enterprise tools.

Investor Backing Signals Structural Shift in Insurance Tech

Agentic AI transforms insurance operations, improving efficiency, scalability, and global service delivery. Source: Created by Ventureburn

Investors see insurance as a key AI transformation sector. Thrive Capital said timing is critical. It believes high-value knowledge work is now being automated. It also said insurance is a major beneficiary of this shift.

Thrive Capital highlighted alignment between product and market need. It said the problem is large and urgent. It also said AI models are now capable of solving it. The firm believes agentic systems will reshape operations across industries.

Sequoia Capital also supported the investment. It sees long-term structural change in insurance workflows. It believes underwriting and claims will become more automated. It also expects improved customer outcomes through AI systems.

Emergence Capital and Pruven Capital also joined the round. Their participation reflects broader enterprise AI momentum. Investors believe agentic systems will become standard in regulated industries.

Pace founder Jamie Cuffe said the company aims to expand insurance coverage globally. He said closing the protection gap requires AI-native operations. He believes automation can scale access to insurance services.

He said the company is already seeing strong adoption. He highlighted faster cycle times and improved efficiency. He added that scaling operations is the next stage. The company plans expansion across the US, Europe, and global markets.

Insurance partners also reported early benefits. WTW said collaboration improves operational performance. It said the partnership strengthens long-term business models. It also said it improves client service delivery outcomes.

More News: Olyzon Raises $10 Million to Build Agentic AI Layer for CTV Media Buying

Global Expansion of AI Insurance Operations Platform

Pace plans to scale its agentic workforce significantly. It aims to complete tens of millions of tasks this year. The company will expand across the United States and Europe. It also plans broader global deployment. The company said insurance systems remain fragmented. Many tools do not communicate effectively. 

This creates inefficiencies across workflows. Pace aims to unify these processes through AI agents. It integrates with existing systems without replacing them. The platform improves execution speed and consistency. It reduces manual intervention in data handling. It also increases accuracy across insurance processes. 

These improvements help insurers manage higher volumes. Pace believes insurance operations will become AI driven. Human teams will focus on oversight and exception handling. AI agents will manage repetitive and structured tasks. This shift will redefine operational roles in insurance firms.

The company continues to invest in infrastructure and engineering. It is expanding its product capabilities. It is also improving system scalability. These upgrades support growing global demand. Pace said its long-term vision is an AI operations layer for insurance. It aims to become the execution engine for the industry. 

It believes agentic systems will define the next phase of insurance infrastructure. Pace’s funding reflects accelerating adoption of AI automation in enterprise systems. Companies are shifting toward agentic workflows to improve efficiency and reduce operational cost.

To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.

The post Pace Raises $46 Million to Scale AI Insurance Operations appeared first on Ventureburn.

Olyzon has raised $10 million in new funding. The round was led by a global venture firm focused on adtech and applied AI. Existing investors also joined the round. The company said the investment supports the next phase of its agentic AI platform. It positions Olyzon to expand its presence in major advertising markets. 

The platform is now live with several leading agencies and brands. Olyzon said the CTV industry has grown rapidly. Media channels expanded. Formats multiplied. Measurement fragmented. Decisioning systems did not keep pace. The company said buyers now face overwhelming complexity.  It believes agentic AI is required to navigate this environment. 

Its platform uses AI agents to qualify inventory, plan media and activate decisions. It also unifies signals from multiple measurement sources into a single set of KPIs. The fundraise will support expansion into the US. It will also enable the opening of a London office.  Olyzon said this helps establish a stronger position in EMEA. 

The company plans further product announcements at an upcoming industry event. It believes global demand for CTV decisioning continues to increase.  It aims to supply the intelligence layer that connects planning, activation and measurement. Olyzon said its system works across every major CTV pipe. 

It supports premium streaming environments, walled gardens, OEM platforms and publisher ad servers. The platform integrates with existing DSPs and SSPs. It does not replace them. It orchestrates them. This approach allows brands to preserve existing infrastructure. It also ensures teams maintain control of activation workflows.

Building the Agentic Layer for Fragmented CTV Channels

Olyzon said the CTV stack has lacked a true intelligence layer. Traditional tools only manage isolated tasks. They do not combine planning, activation and measurement into one system. The company said this creates inefficiency for advertisers. Teams must switch between multiple platforms. 

They also face inconsistent metrics. Olyzon believes this slows campaign optimisation. Industry leaders said the market is shifting. They believe AI agents can now reason across fragmented environments. Olyzon said the technology reached production maturity. Now it can analyse complex channels. It can also adjust decisions in real time. 

This helps improve returns for brands. It also helps teams deliver outcomes that manual workflows cannot achieve. Early users include global agencies and major brands. These clients operate large media budgets. They often face challenges that arise from scale. Olyzon said its system improves clarity. 

It also accelerates activation cycles. The company said its platform learns from every campaign. Over time, it reduces waste. It improves planning accuracy. It strengthens cross-channel performance. Olyzon’s leadership said the rise of AI aligns with shifting advertiser expectations. Buyers want unified planning. 

They want automation that reduces manual work. They want metrics that reflect attention and outcomes. Olyzon said these needs shaped its architecture. It developed an agentic system capable of evaluating millions of signals. It can then respond with steady precision. The company said its goal is to simplify complex CTV markets. 

It views its platform as an infrastructure layer. It is not a replacement for media platforms. It is the intelligence layer that coordinates those platforms. The company said this role mirrors changes across other digital channels. Agentic layers emerge when ecosystems grow too complex for manual processes.

Scaling Operations Across the US and EMEA

Agentic AI platforms scale globally, unifying CTV planning, activation, and measurement across fragmented markets. Source: Created by Ventureburn

The new capital will help the company expand its US operations. Olyzon said it sees strong adoption among North American brands. Many buyers want a unified system that supports planning and activation. They also want clearer measurement frameworks. 

The company believes demand will continue to rise. It plans to increase commercial support across major US hubs. The firm will also open a London office. This supports expansion across EMEA. The company said European buyers face similar challenges. 

Inventory is fragmented. Measurement varies by market. Buyers want greater visibility across channels. They want intelligence that simplifies planning. Olyzon said its agentic system is well placed for this need. It will share new updates on product and partnerships soon. The company said global growth requires strong operational bases. 

It will continue hiring across engineering, product and commercial roles. It also plans to extend support for trading teams. The aim is to provide a complete intelligence ecosystem. Olyzon said this creates a standard workflow. It also improves transparency. Clients gain clearer oversight across CTV supply lines.

The company said the Series A strengthens its long-term roadmap. It will accelerate new AI models. It will deepen integrations. It will expand measurement partnerships. Olyzon said these improvements help clients reduce noise and improve return on spend. It wants to turn complex CTV ecosystems into predictable environments. It believes agentic AI is central to this future.

More News: Longwall Venture Raises £50 Million to Back Early-Stage Deeptech Commercialisation

Reinforcing the Case for Agentic AI in CTV Buying

The company said CTV markets now resemble complex digital supply chains. Advertisers require decisioning tools that function across the entire chain. Olyzon believes agentic systems are the solution. They can navigate multi-layered ecosystems.  They can evaluate signals without fatigue. 

They can coordinate activation faster than manual teams. The company said this is essential in large CTV environments.Industry investors echoed this view. They said the infrastructure layer for CTV buying has not yet been built. They believe Olyzon can supply that layer. 

They praised the platform’s architecture. They said it fills a critical gap. They also said Olyzon’s early results show strong promise. The company said it will continue working with leading brands. It plans to expand adoption across agencies. Olyzon said global brands want attention they can trust. 

They want models that unify metrics. They also want tools that remove guesswork. The company said these needs will define the next phase of CTV. It believes AI agents, not manual decisioning, will drive this phase. The company said it is prepared for this shift. It built its platform to address it.

To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.

The post Olyzon Raises $10 Million to Build Agentic AI Layer for CTV Media Buying appeared first on Ventureburn.

Longwall Venture has raised a £50 million anchor commitment for its latest fund. The capital comes from the British Business Bank through its Enterprise Capital Funds programme. The support strengthens the firm’s long-standing relationship with the institution. The programme has backed Longwall since its first fund in 2008. The new vehicle, Longwall 4, now holds £86.2 million of commitments. The firm is close to its £100 million target.

Longwall said the UK continues to generate strong early-stage science through academic and industrial research. It believes these discoveries face funding gaps during commercial development. The firm said this limits the ability of founders to scale. Managing partner David Denny said the country has a rich pipeline of innovation. He added that strong research requires patient capital. He said the fund will target companies that turn science into usable products.

The new fund will invest between £500,000 and £2 million in early-stage deeptech companies. The firm plans to back up to 16 startups. It will also reserve follow-on capital. The strategy focuses on clean energy, life sciences, advanced manufacturing and defence. Longwall said these sectors require long development cycles. It believes targeted capital can unlock commercial potential.

Longwall has a strong track record in UK deeptech. Its first fund backed OrganOx. The medtech company later sold for more than $1.5 billion. The exit delivered a 19.2x return for investors. The firm said the outcome shows the value of long-term support. Its portfolio today spans medical devices, aerospace and defence.

Growing Deeptech Momentum Across the UK

Industry voices view the British Business Bank’s investment as a positive signal. Mark Sims, managing director at the institution, praised previous outcomes. He said the programme helps early-stage investors raise capital. He added that cornerstone investments help startups secure scale-up funding. He said the new support will uncover the next generation of UK breakthroughs.

Business Secretary Peter Kyle welcomed the commitment. He said the funding provides a boost to the technology sector. He praised the ability of UK research to compete globally. He said the fund helps founders build at home. He noted that scientific development often moves abroad without strong capital support. He believes this investment reinforces the country’s industrial strategy.

Longwall said interest in UK deeptech has accelerated. Research institutions continue to generate patents and prototypes. The firm said this growth encourages specialised investors. It also attracts corporate partners. The new fund will help founders move from lab to market. Longwall said many researchers need guidance on product development. It believes its team can bridge that gap.

The firm remains an active supporter of founder diversity. It does not operate a formal diversity mandate. It is a signatory of the Investing in Women Code. The initiative promotes better access to resources for female entrepreneurs. Longwall said support for diverse founders strengthens the innovation landscape.

Commercialising Scientific Research for Scalable Impact

A visual representation of how strong scientific research evolves into market-ready deeptech innovations through collaboration, patient capital and commercial discipline. Source: Created by Ventureburn.

Longwall said science commercialisation requires more than laboratory progress. Early founders must secure industry partners. They must also meet regulatory standards. Many deeptech founders require patient capital. The firm said this is where specialist investors create value. It aims to support teams from early prototype to market entry.

The firm’s approach evaluates scientific feasibility. It also checks market fit at an early stage. Longwall said this method reduces risk. It also helps teams work with industrial partners. Early funds showed that detailed oversight accelerates progress. OrganOx demonstrated that scientific breakthroughs can reach global markets. The company built major clinical impact through steady investment.

The new fund will target companies working on clean energy systems. It will also invest in emerging life sciences and defence technologies. Longwall said the UK has global strength in these fields. It highlighted advancements in advanced materials, robotics and biotech. The firm said strong science can deliver jobs and export opportunities. It expects the new fund to support these outcomes.

Deeptech companies often require longer timelines than software startups. Longwall said these companies create defensible value. Research builds intellectual property. This protects against competition. Investors view this as a long-term advantage. The firm said strong science combined with commercial discipline produces global winners.

More News: Stord Raises $250 Million Series F at $3 Billion Valuation for Physical Intelligence Commerce Platform

Impact of Anchor Funding on the UK Deeptech Pipeline

Anchor funding signals confidence in the sector. The British Business Bank has backed each Longwall fund. This continuity helps the firm raise capital. It also encourages private investors to join new vehicles. Longwall said this stability supports founders. Startups rely on investors who commit across funding rounds.

Government support also matters. Business Secretary Peter Kyle said UK research drives national competitiveness. He said investment helps the country maintain leadership. The British Business Bank’s involvement ensures that founders across regions receive support. It also helps clusters in Oxford, Cambridge and London grow.

Longwall said its new fund will prioritise companies solving real problems. It believes science must meet commercial needs. The firm expects strong demand for solutions that support sustainable energy. It also sees growth potential in next-generation healthcare. Defence technology also remains a priority. The firm said these sectors require robust funding to scale.

Longwall expects deeptech momentum to continue. It said UK founders now work on global challenges. Investors worldwide monitor UK breakthroughs. Strong exits attract more capital. The firm believes early-stage support remains essential. It plans to maintain long-term relationships with founders.

To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.

The post Longwall Venture Raises £50 Million to Back Early-Stage Deeptech Commercialisation appeared first on Ventureburn.

Stord has raised $250 million in a Series F funding round at a $3 billion valuation. The round marks continued investor confidence in its commerce infrastructure platform. Existing investors led the round and increased their commitments significantly.

The financing included Strike Capital, Kleiner Perkins, Founders Fund, Franklin Templeton, Baillie Gifford, G Squared, Bond, and Lux. The investor base spans venture capital and institutional capital. This signals broad belief in long term infrastructure value.

Stord said the funding will accelerate its fulfilment network and software platform. The company focuses on supporting independent brands. It aims to improve post checkout commerce performance.

Stord Labs Builds Physical AI for Real World Logistics

Stord also launched Stord Labs alongside the funding announcement. This is a dedicated environment for physical intelligence research. It is based at the company’s Atlanta headquarters. Stord Labs develops agentic AI, robotics, and automation systems. 

These systems are tested against live fulfilment operations. The goal is to improve real world logistics performance. The lab runs on the same systems that power production fulfilment.  It operates across nearly 100 facilities. 

This allows rapid deployment of validated innovations. Stord processes over $15 billion in annual gross merchandise value. It also generates billions of data points each year. This data strengthens its AI systems continuously.

The company says every order improves network intelligence. This creates compounding gains in speed and efficiency. It describes this as a physical intelligence flywheel. Stord believes simulation is not enough for robotics development. It argues real operational complexity is required. Stord Labs provides that environment.

Growth, AI Expansion and Acquisition Strategy

AI-driven infrastructure scales global fulfilment networks, unifying logistics, software, and data to improve delivery performance. Source: Created by Ventureburn

Stord has grown revenue around ten times in four years. Growth accelerated after 2023 with AI integration. The software division tripled in 2025. New bookings more than doubled quarter over quarter in early 2026. The company continues to expand its enterprise customer base. Software is now growing faster than logistics operations.

Stord has completed eight acquisitions. Each acquisition exceeded performance expectations. Integration into its platform drives consistent improvements. The company employs more than 4,000 people globally. Over 200 focus on engineering, data science, and infrastructure. These teams support AI and logistics scaling.

Stord operates nearly 100 fulfilment facilities worldwide. It serves over 1,000 customers. Its network reaches nearly one in four US households annually. The company integrates software, data, and physical infrastructure. This enables unified control of fulfilment operations. It also improves customer delivery experience.

More News: Phytolon Raises $23.6 Million Series B Funding for Natural Food Colours

Market Positioning Against Amazon’s Commerce Model

Stord positions itself as an alternative to Amazon’s fulfilment dominance. Amazon controls over one third of US online commerce. Its Prime service reshaped delivery expectations and set new consumer standards. Fast and reliable delivery is now the baseline. 

This shift increased pressure on independent brands. Many struggle to match Amazon’s logistics performance. Stord focuses on the post checkout stage of commerce. It argues this is where brands lose control. Fulfilment directly impacts retention and customer experience.

The company aims to help brands own their customers. It integrates fulfilment, software, and AI into one system. This enables brands to compete at platform scale. Strike Capital described the market shift toward agentic commerce systems. 

It believes integrated infrastructure platforms will dominate the future. Kleiner Perkins also highlighted fulfilment as a source of trust and speed. Stord co founder Sean Henry said Amazon changed expectations through Prime. 

He said independent brands have been structurally disadvantaged. He added that Stord aims to level this playing field. He explained that vertical integration creates compounding gains. Each order improves system efficiency. This strengthens long term performance and scalability.

Stord describes its platform as a physical intelligence layer for commerce. It connects software and logistics in one system. This improves speed, cost, and reliability. The company was founded in 2015 by Sean Henry and Jacob Boudreau. It scaled rapidly during the e commerce boom. It reached unicorn status in 2021.

Stord raised $200 million in 2025 at a $1.5 billion valuation. Total funding now stands at around $775 million. Growth accelerated after AI integration across operations. The company continues expanding its fulfilment and software ecosystem. Its integrated model reshapes post checkout commerce infrastructure.

To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.

The post Stord Raises $250 Million Series F at $3 Billion Valuation for Physical Intelligence Commerce Platform appeared first on Ventureburn.

Phytolon just raised $23.6 million for its Series B round, aiming to grow its natural color platform that runs on fermentation. The company is all about sustainable pigments, hoping to kick old-school synthetic food dyes to the curb. 

Investors are clearly paying attention to clean-label food tech these days—this funding came in three phases, with most of the money landing in April. There’s a strategic investor leading the charge, though they haven’t shared their name. 

Some familiar faces jumped in again, like Millennium Foodtech, NextGen Nutrition, Colorcon Ventures, and Yossi Ackerman. That ongoing backing really says a lot about the faith they have in Phytolon’s future. With this new cash, Phytolon plans to boost production and get a bigger foothold in the US.

FDA Approval Accelerates Commercial Readiness

Phytolon just landed funding right after the FDA gave the green light to its Beetroot Red colorant for food use. That’s a big step—it means food makers can finally start using more natural colors instead of relying on synthetic dyes that come from petroleum. 

Beetroot Red isn’t just beet juice; Phytolon makes it by tweaking baker’s yeast through precision fermentation. That lets them control how much pigment they produce and crank it up for big batches. 

This colorant works well in all kinds of foods because it holds up under heat and doesn’t freak out if the pH changes. Even though the FDA hasn’t set an official rollout date yet, companies are already jumping on board. This approval really puts Phytolon ahead in the clean-label game.

Fermentation Technology and Product Portfolio

Fermentation technology enables scalable production of natural food pigments, reducing reliance on synthetic dyes and agriculture. Source: Created by Ventureburn

Phytolon uses proprietary precision fermentation technology to produce natural pigments. The system engineers baker’s yeast to generate colour compounds. The production organism is removed after fermentation.

The platform is built on two core pigments, yellow and purple. These pigments create a wide colour spectrum. This includes red, orange, pink, and purple shades for food applications. The technology improves production efficiency and consistency. It reduces dependence on agricultural extraction methods. It also strengthens supply stability for food manufacturers.

Phytolon is focusing first on Beetroot Red for commercialisation. It is also developing a prickly pear-based yellow pigment. This expands its future product portfolio. The new funding will support manufacturing scale-up. It will also expand distribution partnerships in the US. Commercial supply chains remain a core focus.

More News: allO Secures $14M to Advance AI Restaurant Operating System

Market Shift and Competitive Landscape

The food industry is shifting away from synthetic dyes. Regulatory pressure and consumer demand are accelerating this transition. Manufacturers are increasingly seeking natural alternatives.

Phytolon operates within this structural market change. Its fermentation platform targets both performance and sustainability needs. It offers an alternative to petroleum-derived colourants. NextGen Nutrition partner James Cali highlighted these trends. He noted rising regulatory scrutiny and consumer preference shifts. He also pointed to advances in fermentation technology.

Cali said Phytolon is well positioned for growth. He highlighted its investor base and FDA approval. He emphasised alignment with long-term industry transformation. Artificial dyes remain widely used in processed foods. However, global regulations are tightening. The US market is moving toward stricter oversight.

Phytolon’s process also reduces environmental impact. It lowers reliance on petrochemical inputs. It improves transparency in ingredient production systems. Phytolon’s Series B reflects increasing venture capital activity in natural food colour technologies. The sector continues to expand as demand for clean-label solutions grows.

Phytolon’s funding positions it for accelerated commercial expansion in the US food market. The company is aligned with regulatory change and consumer demand for natural ingredients. Its fermentation platform supports the shift away from synthetic dyes.

To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.

The post Phytolon Raises $23.6 Million Series B Funding for Natural Food Colours appeared first on Ventureburn.